Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

218.66 -0.91 (-0.41%)
Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Top 5 US Healthcare Stocks By Market Value ↗
Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025. 
Via Stocktwits
News headline image
Legal Seismic Shift: Johnson & Johnson Faces Record $1.5 Billion Talc Verdict as Bankruptcy Strategy Collapses
In a landmark ruling that has sent shockwaves through the corporate legal landscape, a Baltimore jury has ordered Johnson & Johnson (NYSE: JNJ) to pay a staggering $1.56 billion to a single plaintiff.... 
Via MarketMinute
Topics Bankruptcy Bonds Lawsuit
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
News headline image
The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years ↗
These low-risk dividend stocks have the potential to produce a more than 100% total return over the next decade. 
Via The Motley Fool
News headline image
Johnson &amp; Johnson Hit With Record $1.5 Billion US Verdict Over Talc Cancer Claim ↗
Baltimore jury awards $1.5 billion against Johnson & Johnson in record talc-asbestos mesothelioma verdict; company plans to appeal. 
Via Benzinga
News headline image
The Great Consolidation: Why 2026 is Set to Become the 'Year of the Mega-Deal'
As the curtain closes on 2025, the global financial landscape is witnessing a seismic shift in corporate strategy. After two years of "wait-and-see" posturing dictated by high interest rates and... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report
Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment. 
Via Barchart.com
Topics ETFs
News headline image
Why a Minnesota Jury Ordered Johnson &amp; Johnson To Pay $65.5 Million in Damages ↗
Johnson & Johnson has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. 
Via Benzinga
News headline image
The 10% Shadow: Analyzing the Growing Risk of a 30% Market Correction in 2026
As 2025 draws to a close, a sobering forecast from Barron’s has sent ripples through the financial community, suggesting a 10% probability of a massive 30% stock market crash in 2026. While the broader... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Want $10,000 in Passive Income? This Vanguard ETF Could Be Your Ticket to Making It Happen. ↗
Investors would need to have over $330,000 invested in this Vanguard dividend ETF. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
FDA Approves J&amp;J&#39;s New 5-Minute Injection For Lung Cancer ↗
FDA approves Johnson & Johnson's Rybrevant Faspro for EGFR lung cancer and expands TRUFILL use for chronic subdural hematoma treatment. 
Via Benzinga
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
The Yield Search: Why Retirees are Swapping Growth for Defense in a Shifting 2025 Market
As of December 18, 2025, the financial landscape is undergoing a significant transformation, forcing retirees to reconsider their high-octane growth strategies in favor of more stable,... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Rate Cuts Make These 3 Income ETFs More Attractive Than Ever ↗
Via MarketBeat
Topics ETFs
News headline image
The Emotional Rollercoaster: How Fear and Greed Shape Investor Behavior in Market Downturns
The financial markets, often perceived as bastions of rational decision-making, are, in reality, deeply swayed by the powerful currents of human emotion. As the global economy navigates its inherent... 
Via MarketMinute
Topics Bonds Economy Supply Chain
News headline image
The Market's Shifting Sands: Investor Behavior Points to Risk-Off Pivot Amidst Year-End Selloff
The financial markets are currently experiencing a significant recalibration, with investor behavior data as of December 17, 2025, signaling a distinct "risk-off" posture despite underlying bullish... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Investors Rotate Out of Big Tech and AI: A Market Reassessment Underway
As late 2025 draws to a close, a significant recalibration is underway in global financial markets, with investors increasingly rotating capital away from the once-dominant Big Tech and Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
S&P 500 Battles to Break Losing Streak Amidst Economic Uncertainty
The S&P 500, a bellwether for the broader U.S. economy, is facing a critical juncture on December 17, 2025, as it attempts to halt a three-day slide that has wiped billions off market valuations.... 
Via MarketMinute
Topics Economy Retirement Stocks
News headline image
Dow Jones Soars to New Highs Amidst Economic Crosscurrents and AI Jitters
New York, NY – December 17, 2025 – The Dow Jones Industrial Average (DJIA) has concluded December 2025 with a notable ascent, marking a period of robust performance that has seen the index reach new... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast ↗
Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Market Jitters: Stocks Hover Near Session Lows Amidst Mixed Economic Signals and Fed Uncertainty
New York, NY – December 16, 2025 – U.S. equities are treading water in afternoon trading, with major indices hovering near session lows as investors grapple with a complex web of mixed economic data,... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Dow Jones Navigates Treacherous Waters: Is a Historic Loss on the Horizon Amidst Mixed Economic Signals?
The Dow Jones Industrial Average (DJIA) finds itself at a critical juncture in December 2025, having recently scaled unprecedented heights only to face a sudden downdraft that has investors questioning... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall... 
Via MarketMinute
Topics Intellectual Property
News headline image
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most ↗
Via MarketBeat
News headline image
2 Recession-Proof Stocks to Watch in December ↗
These companies have stood the test of time and survived many previous recessions. 
Via The Motley Fool
Topics Economy
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.